Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration

OncoImmunology

Volumn 4, Issue 10, 2015, Pages

  Datta, Jashodeep ^a   Rosemblit, Cinthia ^a   Berk, Erik ^a   Showalter, Lori ^b   Namjoshi, Prachi ^b   Mick, Rosemarie ^a   Lee, Kathreen P ^a   Brod, Andrew M ^a   Yang, Rachel L ^c   Kelz, Rachel R ^a   Fitzpatrick, Elizabeth ^a   Hoyt, Clifford ^d   Feldman, Michael D ^a   Zhang, Paul J ^a   Xu, Shuwen ^a   Koski, Gary K ^b   Czerniecki, Brian J ^a,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b KENT STATE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d PERKINELMER INC   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

breast cancer; CD4+ T helper immunity; dendritic cell; HER2 neu; immune monitoring; immune restoration; vaccination

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G4; INTERLEUKIN 10; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CLONAL ANERGY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOPHENOTYPING; IN VITRO STUDY; INTRADUCTAL CARCINOMA; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TH1 CELL; TUMOR ESCAPE; TUMOR IMMUNITY; VACCINATION; VERY ELDERLY; YOUNG ADULT;

EID: 84934339796     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1022301     Document Type: Article

References (38)

1. A.Jemal, F.Bray, M.M.Center, J.Ferlay, E.Ward, D.Forman. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
2. C.M.Perou, T.Sorlie, M.B.Eisen, M.van de Rijn, S.S.Jeffrey, C.A.Rees, J.R.Pollack, D.T.Ross, H.Johnsen, L.A.Akslen et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52; PMID:10963602; http://dx.doi.org/10.1038/35021093
3. F.Meric, M.C.Hung, G.N.Hortobagyi, K.K.Hunt. HER2/neu in the management of invasive breast cancer. J Am Coll Surg 2002; 194:488-501; PMID:11949754; http://dx.doi.org/10.1016/S1072-7515(02)01121-3
4. E.S.Henson, X.Hu, S.B.Gibson. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 2006; 12:845-53; PMID:16467098; http://dx.doi.org/10.1158/1078-0432.CCR-05-0754
5. G.S.Wang, H.Zhu, S.J.Bi. Pathological features and prognosis of different molecular subtypes of breast cancer. Mol Med Rep 2012; 6:779-82; PMID:22797840; http://dx.doi.org/10.3892/mmr.2012.981
6. R.E.Roses, E.C.Paulson, A.Sharma, J.E.Schueller, H.Nisenbaum, S.Weinstein, K.R.Fox, P.J.Zhang, B.J.Czerniecki. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18:1386-9; PMID:19383888; http://dx.doi.org/10.1158/1055-9965.EPI-08-1101
7. A.Wolf-Yadlin, N.Kumar, Y.Zhang, S.Hautaniemi, M.Zaman, H.D.Kim, V.Grantcharova, D.A.Lauffenburger, F.M.White. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Systems Biol 2006; 2:54; PMID:17016520; http://dx.doi.org/10.1038/msb4100094
8. X.F.Wen, G.Yang, W.Mao, A.Thornton, J.Liu, R.C.Bast, Jr., X.F.Le. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006; 25:6986-96; PMID:16715132; http://dx.doi.org/10.1038/sj.onc.1209685
9. M.J.Piccart-Gebhart, M.Procter, B.Leyland-Jones, A.Goldhirsch, M.Untch, I.Smith, L.Gianni, J.Baselga, R.Bell, C.Jackisch et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72; PMID:16236737; http://dx.doi.org/10.1056/NEJMoa052306
10. P.R.Pohlmann, I.A.Mayer, R.Mernaugh. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 2009; 15:7479-91; PMID:20008848; http://dx.doi.org/10.1158/1078-0432.CCR-09-0636
11. G.Alexe, G.S.Dalgin, D.Scanfeld, P.Tamayo, J.P.Mesirov, C.DeLisi, L.Harris, N.Barnard, M.Martel, A.J.Levine et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 2007; 67:10669-76; PMID:18006808; http://dx.doi.org/10.1158/0008-5472.CAN-07-0539
12. S.M.Mahmoud, E.C.Paish, D.G.Powe, R.D.Macmillan, M.J.Grainge, A.H.Lee, I.O.Ellis, A.R.Green. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037
13. A.Amin, L.C.Benavides, J.P.Holmes, J.D.Gates, M.G.Carmichael, M.T.Hueman, E.A.Mittendorf, C.E.Storrer, Y.H.Jama, D.Craig et al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother 2008; 57:1817-25; PMID:18392824; http://dx.doi.org/10.1007/s00262-008-0509-2
14. R.Bos, L.A.Sherman. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010; 70:8368-77; PMID:20940398; http://dx.doi.org/10.1158/0008-5472.CAN-10-1322
15. J.A.Cintolo, J.Datta, S.J.Mathew, B.J.Czerniecki. Dendritic cell-based vaccines: barriers and opportunities. Future Oncol 2012; 8:1273-99; PMID:23130928; http://dx.doi.org/10.2217/fon.12.125
16. D.C.Parker. T cell-dependent B cell activation. Annu Rev Immunol 1993; 11:331-60; PMID: 8476565
17. C.Gu-Trantien, S.Loi, S.Garaud, C.Equeter, M.Libin, A.de Wind, M.Ravoet, H.Le Buanec, C.Sibille, G.Manfouo-Foutsop et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123:2873-92; PMID:23778140; http://dx.doi.org/10.1172/JCI67428
18. A.Sharma, U.Koldovsky, S.Xu, R.Mick, R.Roses, E.Fitzpatrick, S.Weinstein, H.Nisenbaum, B.L.Levine, K.Fox et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012; 118:4354-62; PMID:22252842; http://dx.doi.org/10.1002/cncr.26734
19. C.Wang, R.King,, M.Feldman, C.Hoyt. Multiplexed characterization of cancer immune response in FFPE biopsies-initial performance of a new approach. J Immunother Cancer 2013; 1(Suppl 1), P54; PMID:24829748; doi: 10.1186/2051-1426-1-S1-P54
20. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
21. P.W.Kantoff, C.S.Higano, N.D.Shore, E.R.Berger, E.J.Small, D.F.Penson, C.H.Redfern, A.C.Ferrari, R.Dreicer, R.B.Sims et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
22. M.Kalos, B.L.Levine, D.L.Porter, S.Katz, S.A.Grupp, A.Bagg, C.H.June. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842
23. S.A.Rosenberg. Cell transfer immunotherapy for metastatic solid cancer–what clinicians need to know. Nat Rev Clin Oncol 2011; 8:577-85; PMID:21808266; http://dx.doi.org/10.1038/nrclinonc.2011.116
24. K.T.Flaherty, I.Puzanov, K.B.Kim, A.Ribas, G.A.McArthur, J.A.Sosman, P.J.O'Dwyer, R.J.Lee, J.F.Grippo, K.Nolop et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19; PMID:20818844; http://dx.doi.org/10.1056/NEJMoa1002011
25. L.C.Benavides, J.D.Gates, M.G.Carmichael, R.Patil, J.P.Holmes, M.T.Hueman, E.A.Mittendorf, D.Craig, A.Stojadinovic, S.Ponniah et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009; 15:2895-904; PMID:19351776; http://dx.doi.org/10.1158/1078-0432.ccr-08-1126
26. M.F.Press, C.Cordon-Cardo, D.J.Slamon. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5:953-62; PMID:1973830
27. A.K.Wesa, M.Mandic, J.L.Taylor, S.Moschos, J.M.Kirkwood, W.W.Kwok, J.H.Finke, W.J.Storkus. Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients. Front Oncol 2014; 4:266; PMID:25325015; http://dx.doi.org/10.3389/fonc.2014.00266
28. M.K.Levings, S.Gregori, E.Tresoldi, S.Cazzaniga, C.Bonini, M.G.Roncarolo. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005; 105:1162-9; PMID:15479730; http://dx.doi.org/10.1182/blood-2004-03-1211
29. U.K.Liyanage, T.T.Moore, H.G.Joo, Y.Tanaka, V.Herrmann, G.Doherty, J.A.Drebin, S.M.Strasberg, T.J.Eberlein, P.S.Goedegebuure et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-61; PMID:12193750; http://dx.doi.org/10.4049/jimmunol.169.5.2756
30. B.Zhang, Z.Wang, L.Wu, M.Zhang, W.Li, J.Ding, J.Zhu, H.Wei, K.Zhao. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PloS One 2013; 8:e57114; PMID:23437326; http://dx.doi.org/10.1371/journal.pone.0057114
31. I.Dogan, A.Cumaoglu, A.Aricioglu, A.Ekmekci. Inhibition of ErbB2 by herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line. Mol Cell Biochem 2011; 347:41-51; PMID:20936496; http://dx.doi.org/10.1007/s11010-010-0610-7
32. Y.Sakai, B.J.Morrison, J.D.Burke, J.M.Park, M.Terabe, J.E.Janik, G.Forni, J.A.Berzofsky, J.C.Morris. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res 2004; 64:8022-8; PMID:15520211; http://dx.doi.org/10.1158/0008-5472.CAN-03-3442
33. R.T.Reilly, J.P.Machiels, L.A.Emens, A.M.Ercolini, F.I.Okoye, R.Y.Lei, D.Weintraub, E.M.Jaffee. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001; 61:880-3; PMID:11221874
34. M.L.Disis, K.H.Grabstein, P.R.Sleath, M.A.Cheever. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5:1289-97; PMID:10389911
35. G.K.Koski, U.Koldovsky, S.Xu, R.Mick, A.Sharma, E.Fitzpatrick, S.Weinstein, H.Nisenbaum, B.L.Levine, K.Fox et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother 2012; 35:54-65; PMID:22130160; http://dx.doi.org/10.1097/CJI.0b013e318235f512
36. R.E.Guerkov, O.S.Targoni, C.R.Kreher, B.O.Boehm, M.T.Herrera, M.Tary-Lehmann, P.V.Lehmann, S.K.Schwander. Detection of low-frequency antigen-specific IL-10-producing CD4(+) T cells via ELISPOT in PBMC: cognate vs. nonspecific production of the cytokine. J Immunol Methods 2003; 279:111-21; PMID:12969552; http://dx.doi.org/10.1016/S0022-1759(03)00240-0
37. H.T.Maecker, J.Hassler, J.K.Payne, A.Summers, K.Comatas, M.Ghanayem, M.A.Morse, T.M.Clay, H.K.Lyerly, S.Bhatia et al. Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol 2008; 9:9; PMID:18366814; http://dx.doi.org/10.1186/1471-2172-9-9
38. S.Ithimakin, K.C.Day, F.Malik, Q.Zen, S.J.Dawsey, T.F.Bersano-Begey, A.A.Quraishi, K.W.Ignatoski, S.Daignault, A.Davis et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 2013; 73:1635-46; PMID:23442322; http://dx.doi.org/10.1158/0008-5472.CAN-12-3349